No-Spa (Drotaverine Hydrochloride)

Drotaverine selectively inhibits phosphodiesterase‑4, which raises intracellular cyclic AMP levels in smooth‑muscle cells. The increased cAMP reduces calcium entry, leading to relaxation of visceral smooth muscle and alleviation of spasm.

The specific dose and frequency are determined by the prescribing clinician based on the indication, patient weight, renal and hepatic function, and the chosen route of administration. No‑Spa is supplied as an injectable solution for intramuscular or intravenous use.

Safety data for drotaverine in pregnancy and lactation are limited. It should only be used if the potential benefit outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Compared with anticholinergic agents such as hyoscine or papaverine, drotaverine has a selective phosphodiesterase‑4 inhibition profile, which may result in fewer anticholinergic side effects like dry mouth or blurred vision. Choice of therapy depends on the specific indication, patient tolerance and physician preference.

No‑Spa must be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Vials should remain in their original packaging until use, and any unused solution should be discarded according to local regulations.

No‑Spa is supplied as a sterile injectable solution and can be given either intramuscularly or intravenously by a qualified healthcare professional. The injection site should be prepared aseptically, and the solution should be used promptly after reconstitution if required.

Serious but uncommon adverse reactions include anaphylactic or severe allergic responses, profound hypotension, cardiac arrhythmias, and hepatic dysfunction. Patients should be monitored for signs of these events, and treatment should be stopped immediately if they occur.

No‑Spa is contraindicated in individuals with known hypersensitivity to drotaverine or any excipients in the formulation. Caution is advised in patients with severe cardiovascular disease, uncontrolled hypertension, or significant liver impairment, and it should be avoided where the risk of severe hypotension outweighs therapeutic benefit.